DaHee Han, PharmD

Most Recent Articles by DaHee Han, PharmD

Jornay PM Approved for the Treatment of ADHD

Jornay PM Approved for the Treatment of ADHD

By

Jornay PM utilizes the proprietary Delexis drug delivery platform which consists of 2 functional film coatings: the first layer delays the initial drug release for up to 10 hours and the second layer helps control the release rate of the active ingredient throughout the day.

Antidepressants and Bleeding Risk: What's the Link?

Antidepressants and Bleeding Risk: What's the Link?

By

Results showed an increased risk of bleeding with SRIs by 1.16-2.36 times with an even higher 3.17- to 10.9-fold risk with concomitant NSAIDs.

Once-Monthly Perseris Approved for the Treatment of Schizophrenia

Once-Monthly Perseris Approved for the Treatment of Schizophrenia

By

Perseris, an atypical antipsychotic, has an extended-release delivery system that releases sustained levels of risperidone over 1 month.

Sugary Drinks, Other Added Sugars May Up Risk for Alzheimer Disease

Sugary Drinks, Other Added Sugars May Up Risk for Alzheimer Disease

By

Drinking sugary beverages has been previously linked to markers of preclinical Alzheimer disease, but the risk associated with consuming added sugars is not established.

Intensive Blood Pressure Control Cuts Combined Mild Cognitive Impairment, Dementia Risk

Intensive Blood Pressure Control Cuts Combined Mild Cognitive Impairment, Dementia Risk

By

In the previous SPRINT study, researchers compared an intensive BP reduction strategy (target systolic BP <120 mmHg) vs standard BP reduction strategy (target systolic BP <140 mmHg).

More Articles by DaHee Han, PharmD

Sign Up for Free e-newsletters